New insights into how the intestine can regulate lipid homeostasis and impact vascular disease: Frontiers for new pharmaceutical therapies to lower cardiovascular disease risk

Canadian Journal of Cardiology

Volumn 27, Issue 2, 2011, Pages 183-191

  Warnakula, Samantha ^a   Hsieh, Joanne ^b   Adeli, Khosrow ^b   Hussain, M Mahmood ^c   Tso, Patrick ^d   Proctor, Spencer D ^a  

^a MAZANKOWSKI ALBERTA HEART INSTITUTE   (Canada)

^b HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^c SUNY DOWNSTATE MEDICAL CENTER   (United States)

^d UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 [3 [[2 CHLORO 3 (TRIFLUOROMETHYL)BENZYL](2 DIPHENYLETHYL)AMINO]PROPOXY]PHENYLACETIC ACID; ANTILIPEMIC AGENT; APOLIPOPROTEIN B48; CHYLOMICRON; CHYLOMICRON REMNANT; CP 346086; DISODIUM ASCORBYL PHYTOSTANOL PHOSPHATE; EXENDIN 4; GLUCAGON LIKE PEPTIDE 1; GW 6340; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LIPOPROTEIN; LOMITAPIDE; MESSENGER RNA; PACTIMIBE; POLOXAMER; SITAGLIPTIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VILDAGLIPTIN; CHOLESTEROL;

ATHEROGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; ENDOPLASMIC RETICULUM; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INTESTINE; INTESTINE CELL; LIPID ABSORPTION; LIPID METABOLISM; NONHUMAN; REVIEW; VASCULAR DISEASE; DRUG EFFECT; HOMEOSTASIS; INCIDENCE; INTESTINE ABSORPTION; METABOLISM; PHYSIOLOGY; PROGNOSIS; RISK FACTOR;

CARDIOVASCULAR DISEASES; CHOLESTEROL; HOMEOSTASIS; HUMANS; HYPOLIPIDEMIC AGENTS; INCIDENCE; INTESTINAL ABSORPTION; INTESTINES; LIPID METABOLISM; PROGNOSIS; RISK FACTORS;

EID: 79958005310     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2010.12.020     Document Type: Review

References (91)

1. WHO, Cardiovascular diseases (CVDs), Fact sheet N°317, January 2011
2. Zilversmit DB. Atherogenic nature of triglycerides, postprandial lipidemia, and triglyceride-rich remnant lipoproteins. Clin Chem 1995;41: 153-8.
3. Cabezas MC, Erkelens DW. Triglycerides and atherosclerosis: To feast or fast. Neth J Med 2000;56:110-8.
4. Proctor SD, Vine DF, Mamo JC. Arterial retention of apolipoprotein B(48)- and B(100)-containing lipoproteins in atherogenesis. Curr Opin Lipidol 2002;13:461-70.
5. Huff MW. Dietary cholesterol, cholesterol absorption, postprandial lipemia and atherosclerosis. Can J Clin Pharmacol 2003;10(suppl A):26A-32A.
6. Karpe F, Steiner G, Uffelman K, Olivecrona T, Hamsten A. Postprandial lipoproteins and progression of coronary atherosclerosis. Atherosclerosis 1994;106:83-97.
7. Twickler T, Dallinga-Thie GM, Chapman MJ, Cohn JS. Remnant lipoproteins and atherosclerosis. Curr Atheroscler Rep 2005;7:140-7.
8. Proctor SD, Mamo JC. Intimal retention of cholesterol derived from apolipoprotein B100- and apolipoprotein B48-containing lipoproteins in carotid arteries of watanabe heritable hyperlipidemic rabbits. Arterioscler Thromb Vasc Biol 2003;23:1595-600.
9. Proctor SD, Vine DF, Mamo JC. Arterial permeability and efflux of apolipoprotein B-containing lipoproteins assessed by in situ perfusion and three-dimensional quantitative confocal microscopy. Arterioscler Thromb Vasc Biol 2004;24:2162-7.
10. Mamo JC, Watts GF, Barrett PH, Smith D, James AP, Pal S. Postprandial dyslipidemia in men with visceral obesity: an effect of reduced LDL receptor expression? Am J Physiol Endocrinol Metab 2001;281:E626-32.
11. Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler Thromb Vasc Biol 1999;19:2474-86.
12. Chan DC, Watts GF, Barrett PH, Mamo JC, Redgrave TG. Markers of triglyceride-rich lipoprotein remnant metabolism in visceral obesity. Clin Chem 2002;48:278-83.
13. Phillips C, Murugasu G, Owens D, Collins P, Johnson A, Tomkin GH. Improved metabolic control reduces the number of postprandial apolipoprotein B-48-containing particles in type 2 diabetes. Atherosclerosis 2000; 148:283-91.
14. Su J, Mary-Magdelena U, Ball G, Proctor S. Postprandial lipemia as an early predictor of cardiovascular complications in childhood obesity. Journal of Clinical Lipidology 2009;3:78-84.
15. Mortimer BC, Holthouse DJ, Martins IJ, Stick RV, Redgrave TG. Effects of triacylglycerol-saturated acyl chains on the clearance of chylomicronlike emulsions from the plasma of the rat. Biochim Biophys Acta 1994; 1211:171-80.
16. Mortimer BC, Kenrick MA, Holthouse DJ, Stick RV, Redgrave TG. Plasma clearance of model lipoproteins containing saturated and polyunsaturated monoacylglycerols injected intravenously in the rat. Biochim Biophys Acta 1992;1127:67-73.
17. Redgrave TG. Chylomicrons in disease: future challenges invited keynote address. Atheroscler Suppl 2008;9:3-6.
18. Redgrave TG, Kodali DR, Small DM. The effect of triacyl-sn-glycerol structure on the metabolism of chylomicrons and triacylglycerol-rich emulsions in the rat. J Biol Chem 1988;263:5118-23.
19. Cesar TB, Oliveira MR, Mesquita CH, Maranhao RC. High cholesterol intake modifies chylomicron metabolism in normolipidemic young men. J Nutr 2006;136:971-6.
20. Martins IJ, Tran JM, Redgrave TG. Food restriction normalizes chylomicron remnant metabolism in murine models of obesity as assessed by a novel stable isotope breath test. J Nutr 2002;132:176-81.
21. Mackintosh V, Redgrave TG. Effects of adrenaline and noradrenaline on clearance of triacylglycerol-rich lipoproteins from plasma: studies with chylomicron-like lipid emulsions in rats. Clin Exp Pharmacol Physiol 1991;18:137-43.
22. Mackintosh VS, Elsegood CL, Redgrave TG. Effects of adrenoreceptor antagonists and agonists on clearance of emulsion models of triacylglycerol-rich lipoproteins from plasma in rats. Clin Exp Pharmacol Physiol 1991;18:775-88.
23. Mackintosh VS, Phan CT, Mortimer BC, Redgrave TG. Vasoactive mediators affect the clearance of lipids from emulsion models of plasma lipoproteins in rats. J Cardiovasc Pharmacol 1996;27:447-54.
24. Yamada T, Kurasawa S, Matsuzaki M, Tanaka A. Remnant lipoprotein metabolism is improved more when body weight is reduced by exercise than by dietary restriction. Clin Chim Acta 2008;388:28-32.
25. Siddiqi SA, Mahan J, Siddiqi S, Gorelick FS, Mansbach CM II. Vesicleassociated membrane protein 7 is expressed in intestinal ER. J Cell Sci 2006;119:943-50.
26. Siddiqi SA, Siddiqi S, Mahan J, Peggs K, Gorelick FS, Mansbach CM II. The identification of a novel endoplasmic reticulum to golgi SNARE complex used by the prechylomicron transport vesicle. J Biol Chem 2006; 281:20974-82.
27. Lindgren FTJensen LCHatch FT. The isolation and quantitative analysis of serum lipoproteins. In: Nelson GJ, ed. Blood Lipids and Lipoproteins: Quantitation, Composition and Metabolism. New York: Wiley, 1972: 181-274.
28. Ockner RK, Hughes FB, Isselbacher KJ. Very low density lipoproteins in intestinal lymph: role in triglyceride and cholesterol transport during fat absorption. J Clin Invest 1969;48:2367-73.
29. Mahley RW, Bennett BD, Morre DJ, Gray ME, Thistlethwaite W, LeQuire VS. Lipoproteins associated with the golgi apparatus isolated from epithelial cells of rat small intestine. Lab Invest 1971;25:435-44.
30. Mattes RD. Oral fat exposure alters postprandial lipid metabolism in humans. Am J Clin Nutr 1996;63:911-7.
31. Mattes RD. Oral fat exposure increases the first phase triacylglycerol concentration due to release of stored lipid in humans. J Nutr 2002;132: 3656-62.
32. Silva KD, Wright JW, Williams CM, Lovegrove JA. Meal ingestion provokes entry of lipoproteins containing fat from the previous meal: possible metabolic implications. Eur J Nutr 2005;44:377-83.
33. Tso P, Drake DS, Black DD, Sabesin SM. Evidence for separate pathways of chylomicron and very low-density lipoprotein assembly and transport by rat small intestine. Am J Physiol 1984;247:G599-610.
34. Luchoomun J, Hussain MM. Assembly and secretion of chylomicrons by differentiated caco-2 cells: nascent triglycerides and preformed phospholipids are preferentially used for lipoprotein assembly. J Biol Chem 1999; 274:19565-72.
35. Tso P, Balint JA. Formation and transport of chylomicrons by enterocytes to the lymphatics. Am J Physiol 1986;250:G715-26.
36. Kondoh M, Yagi K. Progress in absorption enhancers based on tight junction. Expert Opin Drug Deliv 2007;4:275-86.
37. Llback NG. Do surface-active lipids in food increase the intestinal permeability to toxic substances and allergenic agents?. Med Hypotheses 2004; 63:724-30.
38. Kvietys PR, Specian RD, Grisham MB, Tso P. Jejunal mucosal injury and restitution: role of hydrolytic products of food digestion. Am J Physiol 1991;261:G384-91.
39. Kane JP, Hardman DA, Paulus HE. Heterogeneity of apolipoprotein B: isolation of a new species from human chylomicrons. Proc Natl Acad Sci U S A 1980;77:2465-9.
40. Hussain MM. A proposed model for the assembly of chylomicrons. Atherosclerosis 2000;148:1-15.
41. White DA, Bennett AJ, Billett MA, Salter AM. The assembly of triacylglycerol-rich lipoproteins: an essential role for the microsomal triacylglycerol transfer protein. Br J Nutr 1998;80:219-29.
42. Phillips C, Mullan K, Owens D, Tomkin GH. Intestinal microsomal triglyceride transfer protein in type 2 diabetic and non-diabetic subjects: the relationship to triglyceride-rich postprandial lipoprotein composition. Atherosclerosis 2006;187:57-64.
43. Gleeson A, Anderton K, Owens D, et al. The role of microsomal triglyceride transfer protein and dietary cholesterol in chylomicron production in diabetes. Diabetologia 1999;42:944-8.
44. Phillips C, Owens D, Collins P, Tomkin GH. Microsomal triglyceride transfer protein: does insulin resistance play a role in the regulation of chylomicron assembly? Atherosclerosis 2002;160:355-60.
45. Phillips C, Bennett A, Anderton K, et al. Intestinal rather than hepatic microsomal triglyceride transfer protein as a cause of postprandial dyslipidemia in diabetes. Metabolism 2002;51:847-52.
46. Lewis GF, Uffelman K, Naples M, Szeto L, Haidari M, Adeli K. Intestinal lipoprotein overproduction, a newly recognized component of insulin resistance, is ameliorated by the insulin sensitizer rosiglitazone: studies in the fructose-fed syrian golden hamster. Endocrinology 2005; 146:247-55.
47. Iqbal J, Hussain M. Intestinal lipid absorption. Am J Physiol Endocrinol Metab 2009;296:1183-94.
48. Iqbal J, Anwar K, Hussain MM. Multiple, independently regulated pathways of cholesterol transport across the intestinal epithelial cells. J Biol Chem 2003;278:31610-20.
49. Green PH, Tall AR, Glickman RM. Rat intestine secretes discoid high density lipoprotein. J Clin Invest 1978;61:528-34.
50. Brunham LR, Kruit JK, Iqbal J, et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J Clin Invest 2006;116:1052-62.
51. Iqbal J, Hussain MM. Evidence for multiple complementary pathways for efficient cholesterol absorption in mice. J Lipid Res 2005;46:1491-501.
52. Iqbal J, Dai K, Seimon T, et al. IRE1beta inhibits chylomicron production by selectively degrading MTP mRNA. Cell Metab 2008;7:445-55.
53. LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 2002;359:1379-87.
54. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004;364:685-96.
55. Mediene-Benchekor S, Brousseau T, Richard F, Benhamamouch S, Amouyel P, ECTIM Study Group. Blood lipid concentrations and risk of myocardial infarction. Lancet 2001;358:1064-5.
56. Vessby B. Dietary fat, fatty acid composition in plasma and the metabolic syndrome. Curr Opin Lipidol 2003;14:15-9.
57. Mooradian AD. Cardiovascular disease in type 2 diabetes mellitus: current management guidelines. Arch Intern Med 2003;163:33-40.
58. Mamo JC, Wheeler JR. Chylomicrons or their remnants penetrate rabbit thoracic aorta as efficiently as do smaller macromolecules, including low-density lipoprotein, high-density lipoprotein, and albumin. Coron Artery Dis 1994;5:695-705.
59. Proctor SD, Pabla CK, Mamo JC. Arterial intimal retention of proatherogenic lipoproteins in insulin deficient rabbits and rats. Atherosclerosis 2000;149:315-22.
60. Mangat R, Su J, Scott PG, Russell JC, Vine DF, Proctor SD. Chylomicron and apoB48 metabolism in the JCR:LA corpulent rat, a model for the metabolic syndrome. Biochem Soc Trans 2007;35:477-81.
61. Vine DF, Takechi R, Russell JC, Proctor SD. Impaired postprandial apolipoprotein-B48 metabolism in the obese, insulin-resistant JCR:LA-cp rat: increased atherogenicity for the metabolic syndrome. Atherosclerosis 2007;190:282-90.
62. Vine DF, Glimm DR, Proctor SD. Intestinal lipid transport and chylomicron production: possible links to exacerbated atherogenesis in a rodent model of the metabolic syndrome. Atheroscler Suppl 2008;9:69-76.
63. Harbis A, Defoort C, Narbonne H, et al. Acute hyperinsulinism modulates plasma apolipoprotein B-48 triglyceride-rich lipoproteins in healthy subjects during the postprandial period. Diabetes 2001;50:462-9.
64. Federico LM, Naples M, Taylor D, Adeli K. Intestinal insulin resistance and aberrant production of apolipoprotein B48 lipoproteins in an animal model of insulin resistance and metabolic dyslipidemia: evidence for activation of protein tyrosine phosphatase-1B, extracellular signal-related kinase, and sterol regulatory element-binding protein-1c in the fructose-fed hamster intestine. Diabetes 2006;55:1316-26.
65. Haidari M, Leung N, Mahbub F, et al. Fasting and postprandial overproduction of intestinally derived lipoproteins in an animal model of insulin resistance: evidence that chronic fructose feeding in the hamster is accompanied by enhanced intestinal de novo lipogenesis and ApoB48-containing lipoprotein overproduction. J Biol Chem 2002;277:31646-55.
66. Wong DM, Webb JP, Malinowski PM, Xu E, Macri J, Adeli K. Proteomic profiling of intestinal prechylomicron transport vesicle (PCTV)-associated proteins in an animal model of insulin resistance. J Proteomics 2010; 3:1291-305.
67. Qin B, Qiu W, Avramoglu RK, Adeli K. Tumor necrosis factor-alpha induces intestinal insulin resistance and stimulates the overproduction of intestinal apolipoprotein B48-containing lipoproteins. Diabetes 2007;56: 450-61.
68. Meier JJ, Nauck MA. Incretins and the development of type 2 diabetes. Curr Diab Rep 2006;6:194-201.
69. Drucker DJ. The biology of incretin hormones. Cell Metab 2006;3: 153-65.
70. Meier JJ, Gethmann A, Gotze O, et al. Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans. Diabetologia 2006;49:452-8.
71. Qin X, Shen H, Liu M, et al. GLP-1 reduces intestinal lymph flow, triglyceride absorption, and apolipoprotein production in rats. Am J Physiol Gastrointest Liver Physiol 2005;288:G943-9.
72. Hsieh J, Longuet C, Baker CL, et al. The glucagon-like peptide 1 receptor is essential for postprandial lipoprotein synthesis and secretion in hamsters and mice. Diabetologia 2010;53:552-61.
73. Musso G, Gambino R, Pacini G, De Michieli F, Cassader M. Prolonged saturated fat-induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver. Am J Clin Nutr 2009;89:558-67.
74. Miyawaki K, Yamada Y, Ban N, et al. Inhibition of gastric inhibitory polypeptide signaling prevents obesity. Nat Med 2002;8:738-42.
75. Fischer KD, Dhanvantari S, Drucker DJ, Brubaker PL. Intestinal growth is associated with elevated levels of glucagon-like peptide 2 in diabetic rats. Am J Physiol 1997;273:E815-20.
76. Meier JJ, Nauck MA, Pott A, et al. Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 2006;130:44-54.
77. Hsieh J, Longuet C, Xu E, et al. Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production is mediated via CD36. Gastroenterology 2009:137:997-1005.
78. Sobhani I, Bado A, Vissuzaine C, et al. Leptin secretion and leptin receptor in the human stomach. Gut 2000;47:178-83.
79. Morton NM, Emilsson V, Liu YL, Cawthorne MA. Leptin action in intestinal cells. J Biol Chem 1998;273:26194-201.
80. Lu S, Yao Y, Cheng X, et al. Overexpression of apolipoprotein A-IV enhances lipid secretion in IPEC-1 cells by increasing chylomicron size. J Biol Chem 2006;281:3473-83.
81. Iqbal J, Li X, Chang BH, et al. An intrinsic gut leptin melanocortin pathway modulates intestinal microsomal triglyceride transfer protein and lipid absorption. J Lipid Res 2010;51:1929-42.
82. Cuchel M, Bloedon LT, Szapary PO, et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007;356:148-56.
83. Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nat Clin Pract Cardiovasc Med 2008;5:497-505.
84. Chandler CE, Wilder DE, Pettini JL, et al. CP-346086: anMTPinhibitor that lowers plasma total, VLDL, and LDL cholesterol and triglycerides by up to 70% in experimental animals and in humans. J Lipid Res 2003;44: 1887-901.
85. Au WS, Lu LW, Tam S, et al. Pluronic L-81 ameliorates diabetic symptoms in db/db mice through transcriptional regulation of microsomal triglyceride transfer protein. World J Gastroenterol 2009;15:2987-94.
86. Vissers MN, Trip MD, Pritchard PH, et al. Efficacy and safety of disodium ascorbyl phytostanol phosphates in men with moderate dyslipidemia. Eur J Clin Pharmacol 2008;64:651-61.
87. Matikainen N, Mänttäri S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006;49:2049-57.
88. Buse JB, Drucker DJ, Taylor KL, et al; for the DURATION-1 Study Group. DURATION-1: Exenatide once weekly produces sustained glycemic control and weight loss over 52 weeks. Diabetes Care 2010;33: 1255-61.
89. Bunck MC, Diamant M, Eliasson B, et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010;33:1734-7.
90. Yasuda T, Grillot D, Billheimer JT, et al. Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo. Arterioscler Thromb Vasc Biol 2010;30:781-6.
91. Meuwese MC, de Groot E, Duivenvoorden R, et al, CAPTIVATE Investigators. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA 2009;301:1131-9.